
Pharma Pulse: FDA Accelerates Non-Opioid Pain Drug Development, FTC Targets Non-Competes in Healthcare, and DHL Expands Last-Mile Logistics
This episode of Pharma Pulse covers new FDA guidance to speed development of non-opioid pain treatments, the FTC’s warning against non-compete agreements for doctors and nurses, and DHL Supply Chain’s acquisition of SDS Rx to strengthen last-mile healthcare delivery.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new FDA guidance on pain management, an FTC warning on healthcare employment practices, and a major acquisition in healthcare logistics.
The FDA has issued
In other news, the Federal Trade Commission has issued a
Lastly, in supply chain news, DHL Supply Chain has acquired SDS Rx, a company specializing in last-mile healthcare logistics. The
From advancing non-opioid therapies and protecting healthcare workers’ rights to strengthening supply chain resilience, these stories highlight the evolving forces shaping pharma and healthcare today.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.





